Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico

Targeted therapy has changed the paradigm of advanced NSCLC management by improving the survival rate of patients carrying actionable gene alterations using specific inhibitors. The epidemiologic features of these alterations vary among races. Understanding the racial differences benefits drug devel...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-11, Vol.12 (12), p.3492
Main Authors: Zheng, Ruifang, Yin, Zhiwei, Alhatem, Albert, Lyle, Derek, You, Bei, Jiang, Andrew S, Liu, Dongfang, Jobbagy, Zsolt, Wang, Qing, Aisner, Seena, Jiang, Jie-Gen
Format: Article
Language:English
Subjects:
Adenocarcinoma
Age
Cancer therapies
Drug development
Epidemiology
Epidermal growth factor receptors
ErbB-2 protein
Fibroblast growth factor receptor 2
Gender
Gene amplification
Hispanic Americans
Immunotherapy
Kinases
Lung cancer
Medical prognosis
Mutation
Non-small cell lung carcinoma
p53 Protein
Patients
PD-1 protein
PD-L1 protein
Racial differences
Resource allocation
Squamous cell carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted therapy has changed the paradigm of advanced NSCLC management by improving the survival rate of patients carrying actionable gene alterations using specific inhibitors. The epidemiologic features of these alterations vary among races. Understanding the racial differences benefits drug development, clinical trial design, and health resource allocation. Compared to Caucasian and Asian populations, current knowledge on Hispanic patients is less and no data of Hispanic patients from Puerto Rico have been reported. We retrieved and analyzed the demographic, clinical, and molecular data of Hispanic NSCLC patients from Puerto Rico with molecular tests performed in the Genoptix Medical Laboratory in Carlsbad, CA, USA between 2011 and 2018. The majority of the NSCLC patients in our study had either adenocarcinoma (75.4%) or squamous cell carcinoma (15.1%). The incidence of mutations was 24%. They were more common in female and younger patients (
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12123492